{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:11:29Z","timestamp":1789816289630,"version":"4.0.1"},"reference-count":73,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2010,5,31]]},"DOI":"10.2217\/fon.10.48","type":"journal-article","created":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T16:02:09Z","timestamp":1273766529000},"page":"665-679","source":"Crossref","is-referenced-by-count":25,"title":["Abiraterone Acetate: A Promising Drug for the Treatment of Castration-Resistant Prostate Cancer"],"prefix":"10.1080","volume":"6","author":[{"given":"Neeraj","family":"Agarwal","sequence":"first","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah, Salt Lake City, 2000 Circle of Hope, Ste 2123, UT84117, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E","family":"Hutson","sequence":"additional","affiliation":[{"name":"Texas Oncology, PA, Charles A Sammons Cancer Center, Baylor University Medical Center, 3535 Worth St, Dallas, TX75246, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Vogelzang","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics and Co-Chair GU Committee, US Oncology Research, Comprehensive Cancer Centers of NV, 3730 S. Eastern Ave.Las Vegas, NV89169, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[{"name":"Texas Oncology Cancer Center, 501 Medical Center Boulevard, Webster, TX77598, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2010,5,13]]},"reference":[{"key":"e_1_3_3_3_1_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_3_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_3_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22811"},{"key":"e_1_3_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1228"},{"key":"e_1_3_3_3_5_1","unstructured":"Sartor AO OudardS OzgurogluMet al.: Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational Phase III trial (TROPIC). Presented at: Genitourinary Cancer Symposium . San Francisco CA USA 5\u20137 March (2010) (Abstract 9)."},{"key":"e_1_3_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70229-3"},{"issue":"1","key":"e_1_3_3_3_7_1","first-page":"S66","article-title":"The case for secondary hormonal therapies in the chemotherapy age.","volume":"176","author":"Small EJ","year":"2006","unstructured":"Small EJ , RyanCJ: The case for secondary hormonal therapies in the chemotherapy age.J. Urol.176(Suppl. 1), S66\u2013S71 (2006).","journal-title":"J. Urol."},{"key":"e_1_3_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc0765"},{"key":"e_1_3_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncpuro1237"},{"key":"e_1_3_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601127"},{"key":"e_1_3_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.102"},{"key":"e_1_3_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3605"},{"key":"e_1_3_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.102"},{"key":"e_1_3_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951015)76:8<1428::AID-CNCR2820760820>3.0.CO;2-T"},{"key":"e_1_3_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0700420104"},{"key":"e_1_3_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.9.5246"},{"key":"e_1_3_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209020"},{"key":"e_1_3_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021692801278"},{"key":"e_1_3_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0525"},{"key":"e_1_3_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0249"},{"key":"e_1_3_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3332"},{"key":"e_1_3_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2008.08.013"},{"key":"e_1_3_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI110903"},{"key":"e_1_3_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.382"},{"key":"e_1_3_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3461"},{"key":"e_1_3_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1755::AID-CNCR9>3.0.CO;2-D"},{"key":"e_1_3_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1078-1439(00)00123-X"},{"key":"e_1_3_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604904"},{"key":"e_1_3_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.037"},{"key":"e_1_3_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2344"},{"key":"e_1_3_3_3_31_1","doi-asserted-by":"crossref","unstructured":"Nakabayashi M OhWK JacobusSet al.: Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.BJU Int. (2009) (Epub ahead of print).","DOI":"10.1111\/j.1464-410X.2009.08971.x"},{"key":"e_1_3_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp199"},{"issue":"12","key":"e_1_3_3_3_33_1","first-page":"2371","article-title":"Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.","volume":"3","author":"Ellerhorst JA","year":"1997","unstructured":"Ellerhorst JA , TuSM, AmatoRJet al.: Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.Clin. Cancer Res.3(12 Pt 1), 2371\u20132376 (1997).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"e_1_3_3_3_34_1","first-page":"490","article-title":"17 \u03b1-hydroxylase deficiency. A combination of hydroxylation defect and reversible blockade in aldosterone biosynthesis.","volume":"90","author":"Rovner DR","year":"1979","unstructured":"Rovner DR , ConnJW, CohenEL, BerlingerFG, KemDC, GordonDL: 17 \u03b1-hydroxylase deficiency. A combination of hydroxylation defect and reversible blockade in aldosterone biosynthesis.Acta Endocrinol. (Copenh.)90(3), 490\u2013504 (1979).","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"e_1_3_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(94)90131-7"},{"key":"e_1_3_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm981017j"},{"key":"e_1_3_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00021a008"},{"key":"e_1_3_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2007.10.094"},{"key":"e_1_3_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm800355c"},{"key":"e_1_3_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/10629360412331319871"},{"key":"e_1_3_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601879"},{"key":"e_1_3_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.9749"},{"key":"e_1_3_3_3_43_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.5168","article-title":"Crossover pharmacokinetics (PK) study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer.","volume":"26","author":"Carden CP","year":"2008","unstructured":"Carden CP : Crossover pharmacokinetics (PK) study to assess oral administration of abiraterone acetate capsule and tablet formulations in fasted and fed states in patients with prostate cancer.J. Clin. Oncol.26(Suppl.) (2008) (Abstract 5168).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3667"},{"key":"e_1_3_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.09.161"},{"key":"e_1_3_3_3_46_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2008.26.15_suppl.5018","article-title":"Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-\u03b1 hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC)","volume":"26","author":"Ryan C","year":"2008","unstructured":"Ryan C , SmithMR, RosenbergJEet al.: Impact of prior ketoconazole therapy on response proportion to abiraterone acetate, a 17-\u03b1 hydroxylase C17,20-lyase inhibitor in castration resistant prostate cancer (CRPC)J. Clin. Oncol.26(Suppl.) (2008) (Abstract 5018).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_3_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0642"},{"key":"e_1_3_3_3_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0872"},{"key":"e_1_3_3_3_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn544"},{"key":"e_1_3_3_3_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70340-1"},{"key":"e_1_3_3_3_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.5046"},{"key":"e_1_3_3_3_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.6819"},{"key":"e_1_3_3_3_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.9259"},{"key":"e_1_3_3_3_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(88)90295-6"},{"key":"e_1_3_3_3_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.4487"},{"issue":"15","key":"e_1_3_3_3_56_1","article-title":"Antitumor activity of MDV3100 in a Phase I\/II study of castration-resistant prostate cancer (CRPC).","volume":"27","author":"Scher HI","year":"2009","unstructured":"Scher HI , BeerTM, HiganoCSet al.: Antitumor activity of MDV3100 in a Phase I\/II study of castration-resistant prostate cancer (CRPC).J. Clin. Oncol.27(15 Suppl.) (2009) (Abstract 5011).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_3_3_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.10.052"},{"key":"e_1_3_3_3_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000136430.37245.b9"},{"key":"e_1_3_3_3_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.10.014"},{"key":"e_1_3_3_3_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1722"},{"key":"e_1_3_3_3_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0230"},{"key":"e_1_3_3_3_62_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0581"},{"key":"e_1_3_3_3_63_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm040202w"},{"key":"e_1_3_3_3_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)66935-2"},{"key":"e_1_3_3_3_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.2882"},{"key":"e_1_3_3_3_66_1","unstructured":"Schellhammer PF HiganoC BergerERet al.: A randomized double-blind placebo-controlled multi-center Phase III trial of sipuleucel-T in men with metastatic androgen independent prostatic adenocarcinoma (AIPC).Presented at: American Urological Association Annual Meeting . Chicago IL USA 28 April (2009) (Late Breaking Abstract 4)."},{"key":"e_1_3_3_4_2_1","unstructured":"Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy [NCT00638690]. http:\/\/clinicaltrials.gov (Accessed 8 December 2009)"},{"key":"e_1_3_3_4_3_1","unstructured":"Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer [NCT00887198]. http:\/\/clinicaltrials.gov (Accessed 8 December 2009)"},{"key":"e_1_3_3_4_4_1","unstructured":"AFFIRM: A Multinational Phase 3 Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy [NCT00974311]. http:\/\/clinicaltrials.gov (Accessed 14 December 2009)"},{"key":"e_1_3_3_4_5_1","unstructured":"A Phase 1\/2 Open-Label Multiple-Dose Study of the Safety Tolerability and Pharmacokinetics of TAK-700 in Metastatic Androgen-Independent Prostate Cancer Subjects [NCT00569153]. http:\/\/clinicaltrials.gov (Accessed 3 January 2010)"},{"key":"e_1_3_3_4_6_1","unstructured":"Abiraterone Acetate Prednisone and Leuprolide Acetate or Goserelin Before and During Radiation Therapy in Treating Patients With Localized or Locally Advanced Prostate Cancer [NCT01023061]. http:\/\/clinicaltrials.gov (Accessed 14 April 2010)"},{"key":"e_1_3_3_4_7_1","unstructured":"Neoadjuvant Abiraterone Acetate Plus Leuprolide Acetate in Men With Localized High Risk Prostate Cancer [NCT00924469]. http:\/\/clinicaltrials.gov (Accessed 14 April 2010)"},{"key":"e_1_3_3_4_8_1","unstructured":"Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen [NCT01046916]. http:\/\/clinicaltrials.gov (Accessed 14 April 2010)"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon.10.48","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:45:00Z","timestamp":1719125100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon.10.48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,13]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5,31]]}},"alternative-id":["10.2217\/fon.10.48"],"URL":"https:\/\/doi.org\/10.2217\/fon.10.48","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,13]]}}}